📑 Table of Contents (Quick Navigation)
- 1. Eligibility Criteria for Active Surveillance (EAU / AUA / NCCN 2026 Standards)
- 2. Clinical Comparison: Active Surveillance vs. Watchful Waiting vs. Immediate Radical Treatment
- 3. Managing Concurrent Benign Prostatic Hyperplasia (BPH / LUTS) During Active Surveillance
- 4. Frequently Asked Questions (FAQ)
- 5. Medical References (Vancouver Style)
Author & Medical Reviewer: Dr. Dang Phuoc Dat, MD, Specialist Level I – Consultant Urologist, Andrologist & Reconstructive Surgeon (Department of Surgery – Family Hospital Da Nang)
Clinical Executive Summary: For men diagnosed with low-risk localized prostate cancer (ISUP Grade Group 1 / Gleason score 3+3=6, PSA < 10 ng/mL, clinical stage cT1c–cT2a), Active Surveillance (AS) is the gold-standard management strategy recommended by the 2026 European Association of Urology (EAU) and American Urological Association (AUA) guidelines. By closely monitoring tumor biology with serial PSA density/velocity, 3.0 Tesla Multiparametric MRI (mpMRI), and transperineal targeted biopsy, Active Surveillance safely avoids overtreatment—preserving natural urinary continence and erectile potency—while initiating curative intervention promptly if histological upgrading occurs [1, 2].
Many international retirees, expats, and long-term residents relocating to Da Nang, Vietnam are already enrolled in an Active Surveillance protocol initiated in the United States, Europe, or Australia, or are newly diagnosed with a low-grade lesion following a PSA screening test and 3.0T Multiparametric Prostate MRI.
At the Department of Surgery – Family Hospital Da Nang, Dr. Dang Phuoc Dat, MD, Specialist Level I provides seamless, guideline-concordant Active Surveillance follow-up so international and domestic patients can maintain rigorous oncological safety without unnecessary surgery or radiation.
1. Eligibility Criteria for Active Surveillance (EAU / AUA / NCCN 2026 Standards)
Histologically, ISUP Grade Group 1 (Gleason 3+3=6) acinar adenocarcinoma exhibits an extremely indolent natural history, with a near-zero potential for metastasis when confirmed accurately by MRI-targeted biopsy. Under the 15-year ProtecT Trial and PRIAS international registry data, prostate cancer-specific survival on Active Surveillance exceeds 98.5–99% at 10 to 15 years [1, 3].
- Strict Low-Risk Inclusion Criteria (Strong Recommendation):
- Histological Grade: ISUP Grade Group 1 (Gleason score 3+3=6) without cribriform or intraductal carcinoma architecture.
- Serum PSA: Total PSA < 10 ng/mL and PSA Density (PSAD) < 0.15 ng/mL/cm3.
- Clinical Stage: cT1c or cT2a (organ-confined on digital rectal examination and 3.0T mpMRI).
- Selected Favorable Intermediate-Risk Candidates: Men with low-volume ISUP Grade Group 2 (Gleason 3+4=7 with < 10% pattern 4, no cribriform morphology, PSA < 10 ng/mL, and PSAD < 0.15) who prioritize preservation of sexual and urinary quality of life may also be managed on an intensified Active Surveillance schedule [1, 2].
🗓️ Standardized EAU / PRIAS Active Surveillance Timetable at Family Hospital Da Nang
• Every 3 to 6 Months: Total PSA, Free/Total PSA ratio, PSA Density calculation, and Digital Rectal Examination (DRE) using the same calibrated laboratory assay.
• Every 12 to 18 Months: High-resolution 3.0 Tesla Multiparametric Prostate MRI (mpMRI) scored via PI-RADS v2.1 and PRECISE radiological progression criteria (PRECISE 1–5) to verify lesion stability.
• Confirmatory / Per-Protocol Biopsy: Transperineal MRI-Targeted Biopsy performed at 12 months (if not done via MRI fusion initially) or triggered immediately if mpMRI shows radiological progression (PRECISE score 4–5) or PSA density rises above 0.20 ng/mL/cm3 [1, 2].
2. Clinical Comparison: Active Surveillance vs. Watchful Waiting vs. Immediate Radical Treatment
| Clinical Feature | Active Surveillance (AS) | Watchful Waiting (WW) | Immediate Radical Prostatectomy / Radiation |
|---|---|---|---|
| Therapeutic Intent | Curative intent (timed intervention only if tumor upgrades) | Palliative intent (symptom control only) | Immediate curative ablation/removal |
| Target Patient Profile | Fit men with life expectancy > 10 years and low-risk ISUP Grade 1 tumor | Frail men with severe comorbidities and life expectancy < 10 years | Unfavorable intermediate-risk (ISUP 3) or high-risk (ISUP 4–5) disease |
| Monitoring Protocol | PSA every 3–6 mos, 3.0T mpMRI every 12–18 mos, Transperineal Biopsy | Symptom-driven assessment; no routine MRI or repeat biopsies | Post-treatment ultrasensitive PSA monitoring |
| Continence & Erectile Function | 100% baseline preservation while on surveillance | Preserved until local progression occurs | Risk of stress urinary incontinence (5–15%) and erectile dysfunction (30–60%) |
3. Managing Concurrent Benign Prostatic Hyperplasia (BPH / LUTS) During Active Surveillance
A frequent clinical challenge for men on Active Surveillance is the coexistence of an enlarged prostate (BPH) causing nocturia, weak stream, or elevated PSA levels due to benign stromal hyperplasia. Dr. Dang Phuoc Dat applies a structured dual-management protocol:
- PSA Density (PSAD) Calibration: Measuring exact prostate volume via TRUS or 3.0T MRI allows accurate calculation of PSA Density (Total PSA divided by prostate volume). A rising PSA driven by a 75 mL benign prostate (PSAD < 0.12) is distinguished clearly from malignant progression.
- 5-Alpha Reductase Inhibitor (5-ARI) Interpretation Rule: If a patient on Active Surveillance takes Finasteride or Dutasteride for BPH, serum PSA decreases by approximately 50% within 6 months. Any confirmed rise above the new nadir on 5-ARI therapy warrants immediate 3.0T mpMRI re-evaluation [1, 2].
🚨 Triggers for Transitioning from Active Surveillance to Curative Treatment
- Histological Upgrading on Repeat Biopsy: Reclassification to ISUP Grade Group 2 with cribriform/intraductal features, or ISUP Grade Group ≥ 3 (Gleason 4+3=7 or higher) [1].
- Radiological Progression on 3.0T mpMRI (PRECISE Score 4 or 5): Significant increase in index lesion volume, drop in ADC diffusion values, or suspicion of extracapsular extension (cT3a) confirmed by targeted biopsy.
- Patient Preference / Surveillance Anxiety: Note that PSA doubling time alone (< 3 years) is no longer used as a standalone trigger for radical surgery without MRI and histological biopsy confirmation [1, 2].
4. Frequently Asked Questions (FAQ)
Question 1: Is it safe to delay prostate cancer surgery while on Active Surveillance?
Yes, for properly selected ISUP Grade Group 1 patients who adhere to scheduled PSA and 3.0T mpMRI follow-up. Long-term data from the ProtecT Trial (15-year follow-up published in the New England Journal of Medicine) proved that men assigned to active monitoring had the same 97% prostate cancer-specific survival as those who underwent immediate surgery or radiotherapy, while avoiding years of urinary leakage and sexual dysfunction [3].
Question 2: Can I continue my US, European, or Australian Active Surveillance schedule in Da Nang?
Yes. Bring your prior biopsy pathology report, baseline MRI dicom/report, and historical PSA log to Room 326 – Department of Surgery, Family Hospital Da Nang. We synchronize your lab testing, 3.0T mpMRI PI-RADS/PRECISE reporting, and English clinical documentation so your records remain fully compatible with your home-country urology center.
Question 3: Does a singlePSA spike mean my cancer has progressed?
Not necessarily. Transient PSA spikes are frequently caused by subclinical prostatitis, urinary tract infection, recent ejaculation, cycling, or urological instrumentation. We repeat the PSA test after 4 to 6 weeks (excluding UTI) and evaluate PSA Density and 3.0T mpMRI before recommending a repeat biopsy [1, 2].
5. Medical References (Vancouver Style)
- Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Arnhem: European Association of Urology; 2026.
- Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Journal of Urology. 2022;208(1):10-33.
- Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT Trial). New England Journal of Medicine. 2023;388(17):1547-1558.
Medical Disclaimer: This clinical guide is authored and medically reviewed by Dr. Dang Phuoc Dat for educational purposes and does not replace individualized oncological consultation.
Dr. Dang Phuoc Dat, MD, Specialist Level I – Consultant Urologist, Andrologist & Reconstructive Surgeon (10+ years clinical experience).
📞 English Hotline / WhatsApp / Zalo: 07777 43 777 (+84 777 743 777) | WhatsApp Direct: wa.me/84777743777 | Websites: tuyentienliet.com & bacsidanang.com
Select any symptoms or concerns you are currently experiencing to see your recommended triage level before messaging Dr. Dang Phuoc Dat:


